Clinical trial · Observational
Early Lymph Node Metastasis in T1/2 Stage Colorectal Cancer: Molecular and Clinical Insights
NCT06130644CI-TRIAL-00071324completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The prognostic implications of lymph node metastasis in colorectal cancer patients at an early stage, specifically T1/2 stage, are relatively unfavorable. Therefore, understanding the clinical and molecular traits relevant to metastasis in T1/2 stage are of substantial clinical importance.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Patients with lymph node metastasis
- description
- T1/2N+ patients
- label
- Patients without lymph node metastasis
- description
- T1/2N- patients
Primary outcomes (1)
- measure
- MSI status
- timeFrame
- through study completion, an average of 1 year
- description
- (I) MSI-High (MSI-H) if two or more mononucleotide markers in tumor tissue had size variations of ≥3bp compared to normal tissue; (II) MSI-Low (MSI-L) if a single mononucleotide marker in tumor tissue exhibited a size variation of ≥3bp compared to normal tissue; (III) Microsatellite Stable (MSS) if there were no size variations of ≥3bp in mononucleotide markers in tumor tissue compared to normal tissue.
Secondary outcomes (2)
- measure
- Somatic Mutation Distribution
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Men and women aged 18-75 years old; * Clinical staged T2; * Histologically proven colon or rectal adenocarcinoma. Exclusion Criteria: * Patients over 80 years of age; * Recurrent colorectal cancer; * Multiple primary tumors; * Distant metastasis.
References
Publications (0)
Data not yet available
No reference posted for this study.